10-Q: Lineage Cell Therapeutics Reports Second Quarter 2024 Financial Results, Provides Business Update

Lineage Cell Therapeutics reported a net loss of $12.3 million for the first half of 2024, with a decrease in collaboration revenue offset by reduced research and development expenses.

Summary

• Lineage Cell Therapeutics, a clinical-stage biotechnology company, released its financial results for the second quarter of 2024.
• The company reported a net loss of $5.76 million for the three months ended June 30, 2024, and a net loss of $12.3 million for the six months ended June 30, 2024.
• Collaboration revenues decreased to $1.1 million for the quarter and $2.3 million for the six-month period, primarily due to adjustments in estimated costs under the Roche Agreement.
• Research and development expenses decreased to $2.9 million for the quarter and $5.9 million for the six-month period, reflecting reduced spending across multiple programs.
• General and administrative expenses increased slightly to $4.4 million for the quarter and $9.4 million for the six-month period.
• The company's cash, cash equivalents, and marketable securities totaled $38.5 million as of June 30, 2024.
• Lineage believes its current resources will be sufficient to fund operations for at least the next twelve months.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there are positives such as cost management and a strong cash position, the significant decrease in collaboration revenue and the ongoing operating losses are concerning. The delay in the FDA review and the risks associated with the Israel-Hamas war further contribute to a negative sentiment.

Positives

• Research and development expenses decreased year-over-year, indicating cost management.
• The company believes its current cash and marketable securities are sufficient to fund operations for at least the next twelve months.
• Lineage continues to advance its pipeline of allogeneic cell therapy programs, including OpRegen and OPC1.
• The company entered into a service agreement with Genentech to support the OpRegen program.

Negatives

• The company experienced a significant decrease in collaboration revenues compared to the same periods in the prior year.
• Lineage continues to incur significant operating losses.
• The review of the IND amendment for OPC1 by the FDA is still ongoing due to workload and conflicting priorities at the agency.

Risks

• The company's manufacturing operations are located in Jerusalem, Israel, and are subject to risks associated with the ongoing Israel-Hamas war.
• The company may need to raise additional capital in the future to fund its operations.
• The company's product development programs are subject to regulatory risks and uncertainties.
• The company's financial results may be impacted by fluctuations in foreign currency exchange rates.

Future Outlook

The company believes its current cash, cash equivalents, and marketable securities will be sufficient to fund planned operations for at least twelve months from the issuance date of the financial statements.

Management Comments

• The company continues to focus on customary trial preparations and related activities to support opening our first clinical study site for the DOSED study.
• The company intends to open its first clinical study site as soon as feasible following confirmation that the FDA has no further feedback or additional information requests relating to our IND amendment.

Industry Context

The company is operating in the competitive field of cell therapy, focusing on allogeneic, or off-the-shelf, therapies. The company's collaboration with Roche highlights the potential of its technology platform in the treatment of ocular disorders. The ongoing war in Israel adds a layer of complexity to the company's operations, as its manufacturing facility is located in Jerusalem.

Comparison to Industry Standards

• Lineage's financial results are typical for a clinical-stage biotechnology company, with significant operating losses and reliance on external funding.
• The decrease in research and development expenses may indicate a shift in focus or cost-cutting measures, which is not uncommon in the biotech industry.
• The company's collaboration with Roche is a positive sign, as it provides a source of revenue and validation of its technology.
• The delay in the FDA review of the IND amendment for OPC1 is a common challenge faced by companies in the biotech industry.

Legal Proceedings

• The company is not currently subject to any pending material litigation, other than ordinary routine litigation incidental to its business.
• A putative class action lawsuit challenging the Asterias Merger was settled in February 2023.

Related Party Transactions

• Broadwood Partners, L.P., which is affiliated with Neal Bradsher, a member of the board of directors, purchased 6,730,770 common shares in a registered direct offering.
• Don Bailey, a member of the board of directors, purchased 96,155 shares in the same offering.

Stakeholder Impact

• Shareholders may be concerned about the company's ongoing losses and the decrease in collaboration revenue.
• Employees may be affected by the ongoing war in Israel and potential disruptions to operations.
• Customers and partners may be impacted by delays in the company's product development programs.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• The company plans to open its first clinical study site for the DOSED study as soon as feasible following confirmation from the FDA.
• The company plans to apply for additional funding from CIRM for continued clinical development of OPC1 for the treatment of SCI.

Key Dates

Keywords

cell therapy, biotechnology, OpRegen, OPC1, clinical trials, allogeneic, retinal pigmented epithelial cells, oligodendrocyte progenitor cells, spinal cord injury, geographic atrophy, age-related macular degeneration